Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education

Gustavo Saposnik, Jorge Maurino, Angel P Sempere, Maria A Terzaghi, Christian C Ruff, Muhammad Mamdani, Philippe N Tobler, Xavier Montalban, Gustavo Saposnik, Jorge Maurino, Angel P Sempere, Maria A Terzaghi, Christian C Ruff, Muhammad Mamdani, Philippe N Tobler, Xavier Montalban

Abstract

Background: Physicians often do not initiate or intensify treatments when clearly warranted, a phenomenon known as therapeutic inertia (TI). Limited information is available on educational interventions to ameliorate knowledge-to-action gaps in TI.

Objectives: To evaluate the feasibility and efficacy of an educational intervention compared to usual care among practicing neurologists caring for patients with multiple sclerosis (MS).

Methods: We conducted a pilot double-blind, parallel-group, randomized clinical trial. Inclusion criteria included neurologists who are actively involved in managing MS patients. Participants were exposed to 20 simulated case-scenarios (10 cases at baseline, and 10 cases post-randomization to usual care vs. educational intervention) of relapsing-remitting MS with moderate or high risk of disease progression. The educational intervention employed a traffic light system (TLS) to facilitate decisions, allowing participants to easily recognize high-risk scenarios requiring treatment escalation. We also measured differences between blocks to invoke decision fatigue. The control group responded as they would do in their usual clinical practice not exposed to the educational intervention. The primary feasibility outcome was the proportion of participants who completed the study and the proportion of participants who correctly identified a high-risk case-scenario with the "red traffic light." Secondary outcomes included decision fatigue (defined as an increment of TI in the second block of case-scenarios compared to the first block) and the efficacy of the educational intervention measured as a reduction in TI for MS treatment.

Results: Of 30 neurologists invited to be part of the study, the participation rate was 83.3% (n = 25). Of the 25 participants, 14 were randomly assigned to the control group and 11 to the intervention group. TI was present in 72.0% of participants in at least one case scenario. For the primary feasibility outcome, the completion rate of the study was 100% (25/25 participants). Overall, 77.4% of participants correctly identified the "red traffic light" for clinical-scenarios with high risk of disease progression. Similarly, 86.4% of participants correctly identified the "yellow traffic light" for cases that would require a reassessment within 6-12 months. For the secondary fatigue outcome, within-group analysis showed a significant increased prevalence of TI in the second block of case-scenarios (decision fatigue) among participants randomized to the control group (TI pre-intervention 57.1% vs. TI post-intervention 71.4%; p = 0.015), but not in the active group (TI pre-intervention 54.6% vs. TI post-intervention 63.6%; p = 0.14). For the efficacy outcome, we found a non-significant reduction in TI for the targeted intervention compared to controls (22.6 vs. 33.9% post-intervention; OR 0.57; 95% CI 0.26-1.22).

Conclusion: An educational intervention applying the TLS is feasible and shows some promising results in the identification of high-risk scenarios to reduce decision fatigue and TI. Larger studies are needed to determine the efficacy of the proposed educational intervention.

Clinical trial registration: www.ClinicalTrials.gov, identifier NCT03134794.

Keywords: decision making; disease-modifying therapy; multiple sclerosis; neuroeconomics; risk aversion.

Figures

Figure 1
Figure 1
CONSORT flow diagram.
Figure 2
Figure 2
Description of the educational intervention according to the GREET guidelines.
Figure 2
Figure 2
Description of the educational intervention according to the GREET guidelines.
Figure 2
Figure 2
Description of the educational intervention according to the GREET guidelines.
Figure 3
Figure 3
Educational intervention: the traffic light system may facilitate therapeutic decisions in multiple sclerosis care. Participants viewed the two informative panels (A,B) and a third panel providing an example (C).
Figure 3
Figure 3
Educational intervention: the traffic light system may facilitate therapeutic decisions in multiple sclerosis care. Participants viewed the two informative panels (A,B) and a third panel providing an example (C).
Figure 4
Figure 4
Prevalence of therapeutic inertia (TI) for the targeted intervention accounting for each individual response in the active and control groups. Lower numbers represent lower TI (more optimal therapeutic decisions). *p = 0.74, **p = 0.12. Note the lower trend in the prevalence of TI in the intervention group compared to the control group (22.6 vs. 33.9%; OR 0.57; 95% CI 0.26–1.22).

References

    1. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro heart survey on atrial fibrillation. Am Heart J (2007) 153(6):1006–12.10.1016/j.ahj.2007.03.008
    1. O’Connor PJ, Sperl-Hillen JAM, Johnson PE, Rush WA, Biltz G. Clinical inertia and outpatient medical errors. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation. (Vol. 2), Rockville, MD: Concepts and Methodology; (2005).
    1. Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, et al. Optimizing treatment success in multiple sclerosis. J Neurol (2016) 263(6):1053–65.10.1007/s00415-015-7986-y
    1. Saposnik G, Sempere AP, Prefasi D, Selchen D, Ruff CC, Maurino J, et al. Decision-making in multiple sclerosis: the role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS). Front Neurol (2017) 8:65.10.3389/fneur.2017.00065
    1. Mohan AV, Phillips LS. Clinical inertia and uncertainty in medicine. JAMA (2011) 306(4):383; author reply–4.10.1001/jama.2011.1045
    1. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med (2001) 135(9):825–34.10.7326/0003-4819-135-9-200111060-00012
    1. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension (2006) 47(3):345–51.10.1161/01.HYP.0000200702.76436.4b
    1. Lebeau JP, Cadwallader JS, Aubin-Auger I, Mercier A, Pasquet T, Rusch E, et al. The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review. BMC Fam Pract (2014) 15:130.10.1186/1471-2296-15-130
    1. Lebeau JP, Cadwallader JS, Vaillant-Roussel H, Pouchain D, Yaouanc V, Aubin-Auger I, et al. General practitioners’ justifications for therapeutic inertia in cardiovascular prevention: an empirically grounded typology. BMJ Open (2016) 6(5):e010639.10.1136/bmjopen-2015-010639
    1. Simon D. Therapeutic inertia in type 2 diabetes: insights from the PANORAMA study in France. Diabetes Metab (2012) 38(Suppl 3):S47–52.10.1016/S1262-3636(12)71534-3
    1. Dijkstra IS, Pols J, Remmelts P, Brand PL. Preparedness for practice: a systematic cross-specialty evaluation of the alignment between postgraduate medical education and independent practice. Med Teach (2015) 37(2):153–61.10.3109/0142159X.2014.929646
    1. Cook DA, Hatala R, Brydges R, Zendejas B, Szostek JH, Wang AT, et al. Technology-enhanced simulation for health professions education: a systematic review and meta-analysis. JAMA (2011) 306(9):978–88.10.1001/jama.2011.1234
    1. Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes (2017) 11:3–12.10.1016/j.pcd.2016.09.003
    1. Cooke CE, Sidel M, Belletti DA, Fuhlbrigge AL. Review: clinical inertia in the management of chronic obstructive pulmonary disease. COPD (2012) 9(1):73–80.10.3109/15412555.2011.631957
    1. Orriols L, Delorme B, Gadegbeku B, Tricotel A, Contrand B, Laumon B, et al. Prescription medicines and the risk of road traffic crashes: a French registry-based study. PLoS Med (2010) 7(11):e1000366.10.1371/journal.pmed.1000366
    1. Sonnenberg L, Gelsomin E, Levy DE, Riis J, Barraclough S, Thorndike AN. A traffic light food labeling intervention increases consumer awareness of health and healthy choices at the point-of-purchase. Prev Med (2013) 57(4):253–7.10.1016/j.ypmed.2013.07.001
    1. Hawley KL, Roberto CA, Bragg MA, Liu PJ, Schwartz MB, Brownell KD. The science on front-of-package food labels. Public Health Nutr (2013) 16(3):430–9.10.1017/S1368980012000754
    1. Murphy MS, Baker M. When used appropriately, NICE’s traffic light system for febrile children helps clinicians make safe and appropriate decisions. BMJ (2014) 348:g2518.10.1136/bmj.g2518
    1. Enax L, Krajbich I, Weber B. Salient nutrition labels increase the integration of health attributes in food decision-making. Judgment Decis Mak (2016) 11(5):460–71.
    1. Saposnik G, Sempere AP, Raptis R, Prefasi D, Selchen D, Maurino J. Decision making under uncertainty, therapeutic inertia, and physicians’ risk preferences in the management of multiple sclerosis (DIScUTIR MS). BMC Neurol (2016) 16(1):58.10.1186/s12883-016-0577-4
    1. Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M. Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA (2000) 283(13):1715–22.10.1001/jama.283.13.1715
    1. Peabody JW, Luck J, Glassman P, Jain S, Hansen J, Spell M, et al. Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann Intern Med (2004) 141(10):771–80.10.7326/0003-4819-141-10-200411160-00008
    1. Kohok DD, Shah S, Kumar R, Venuto L, Gudleski G, Venuto R. Interventions to reduce clinical inertia in cardiac risk factor management in renal transplant recipients. J Clin Hypertens (Greenwich) (2014) 16(2):127–32.10.1111/jch.12249
    1. Gongora-Ortega J, Segovia-Bernal Y, Valdivia-Martinez Jde J, Galaviz-DeAnda JM, Prado-Aguilar CA. Educational interventions to improve the effectiveness in clinical competence of general practitioners: problem-based versus critical reading-based learning. BMC Med Educ (2012) 12:53.10.1186/1472-6920-12-53
    1. Kennedy T, Regehr G, Rosenfield J, Roberts SW, Lingard L. Exploring the gap between knowledge and behavior: a qualitative study of clinician action following an educational intervention. Acad Med (2004) 79(5):386–93.10.1097/00001888-200405000-00006
    1. Phillips AC, Lewis LK, McEvoy MP, Galipeau J, Glasziou P, Moher D, et al. Development and validation of the guideline for reporting evidence-based practice educational interventions and teaching (GREET). BMC Med Educ (2016) 16(1):237.10.1186/s12909-016-0759-1
    1. Enax L, Hu Y, Trautner P, Weber B. Nutrition labels influence value computation of food products in the ventromedial prefrontal cortex. Obesity (Silver Spring) (2015) 23(4):786–92.10.1002/oby.21027
    1. Prosperini L, Mancinelli CR, De Giglio L, De Angelis F, Barletta V, Pozzilli C. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Mult Scler (2014) 20(5):566–76.10.1177/1352458513502399
    1. Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol (2013) 73(1):95–103.10.1002/ana.23758
    1. Sormani MP, Rio J, Tintore M, Signori A, Li D, Cornelisse P, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler (2013) 19(5):605–12.10.1177/1352458512460605
    1. Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, et al. Assessing response to interferon-beta in a multicenter dataset of patients with MS. Neurology (2016) 87(2):134–40.10.1212/WNL.0000000000002830
    1. Sormani MP, De Stefano N. Defining and scoring response to IFN-beta in multiple sclerosis. Nat Rev Neurol (2013) 9(9):504–12.10.1038/nrneurol.2013.146
    1. Tramacere I, Del Giovane C, Salanti G, D’Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev (2015) 9:CD011381.10.1002/14651858.CD011381.pub2
    1. Prosperini L, Gianni C, Leonardi L, De Giglio L, Borriello G, Galgani S, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler (2012) 18(1):64–71.10.1177/1352458511417481
    1. Garcia-Merino A, Fernandez O, Montalban X, de Andres C, Oreja-Guevara C, Rodriguez-Antiguedad A, et al. Consensus statement on medication use in multiple sclerosis by the Spanish Society of Neurology’s study group for demyelinating diseases. Neurologia (2013) 28(6):375–8.10.1016/j.nrl.2013.01.009
    1. Ancker JS, Edwards A, Nosal S, Hauser D, Mauer E, Kaushal R, et al. Effects of workload, work complexity, and repeated alerts on alert fatigue in a clinical decision support system. BMC Med Inform Decis Mak (2017) 17(1):36.10.1186/s12911-017-0430-8
    1. Stewart AF, Ferriero DM, Josephson SA, Lowenstein DH, Messing RO, Oksenberg JR, et al. Fighting decision fatigue. Ann Neurol (2012) 71(1):A5–15.10.1002/ana.23531
    1. Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC, Gold R. Multiple sclerosis decision model (MSDM): Entwicklung eines Mehrfaktorenmodells zur Beurteilung des Therapie- und Krankheitsverlaufs bei schubförmiger Multipler Sklerose. Akt Neurol (2013) 40(09):486–93.10.1055/s-0033-1349643

Source: PubMed

3
Abonneren